Astellas

Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
BioSpace
Merck
Seagen
Astellas
urothelial cancer
clinical trials
bladder cancer
Padcev
Keytruda
Flag link:
Taysha ends work on gene therapy after Astellas walks away, FDA requests randomized trial
Taysha ends work on gene therapy after Astellas walks away, FDA requests randomized trial
Fierce Biotech
Astellas
Taysha Gene Therapies
gene therapy
FDA
Flag link:
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of Izervay for Geographic Atrophy
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of Izervay for Geographic Atrophy
PR Newswire
Astellas
clinical trials
Izervay
geographic atrophy
Flag link:
EU clears review of Xtandi in earlier-stage prostate cancer
EU clears review of Xtandi in earlier-stage prostate cancer
Pharmaphorum
EMA
Europe
Astellas
Pfizer
prostate cancer
Xtandi
Flag link:
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
Reuters
Astellas
Medicare
prostate cancer
Xtandi
drug pricing
Inflation Reduction Act
Flag link:
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
BioSpace
patent cliff
patents
Takeda
Vyvanse
Pfizer
Eraxis
JNJ
Stelara
Merck
Isentress
Eiger Pharmaceuticals
Zokinvy
Astellas
Myrbetriq
Novartis
Entresto
Amgen
Otzela
Flag link:
The 10 drugs that CMS might wrangle into negotiations
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
CMS
Medicare
drug pricing
Bristol Myers Squibb
Janssen
Merck
Pfizer
Amgen
Boehringer Ingelheim
Pharmacyclics
AstraZeneca
Astellas
GSK
Flag link:
Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood
Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood
PR Newswire
Astellas
Cambridge MA
R&D
Flag link:
Iveric drug approved for type of vision loss as rival’s safety draws scrutiny
Iveric drug approved for type of vision loss as rival’s safety draws scrutiny
BioPharma Dive
Iveric Bio
geographic atrophy
FDA
Izervay
Astellas
Flag link:
Go or no go? Biogen and Astellas head towards key PDUFAs
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
FDA
Astellas
Zimura
Biogen
SAGE Therapeutics
zuranolone
major depressive disorder
postpartum depression
geographic atrophy
Flag link:
Astellas notches another protein degrader pact with $21M upfront for PeptiDream
Astellas notches another protein degrader pact with $21M upfront for PeptiDream
Fierce Biotech
Astellas
protein degradation
PeptiDream
Flag link:
Astellas' Zolbetuximab Is a Promising Therapy for HER2-Negative Gastric Cancer
Astellas' Zolbetuximab Is a Promising Therapy for HER2-Negative Gastric Cancer
Xtalks
Astellas
zolbetuximab
gastric cancer
FDA
EMA
Flag link:
Astellas buys rights to 4D Molecular’s technology in latest gene therapy deal
Astellas buys rights to 4D Molecular’s technology in latest gene therapy deal
BioPharma Dive
Astellas
4D Molecular Therapeutics
gene therapy
viral vectors
Flag link:
Astellas to withhold prostate cancer drug from contract pharmacies
Astellas to withhold prostate cancer drug from contract pharmacies
Beckers Hospital Review
Astellas
340B
Xtandi
prostate cancer
Flag link:
Biopharma buyouts bounce back
Biopharma buyouts bounce back
EP Vantage
M&A
Amgen
Astellas
Eli Lilly
GSK
Horizon Therapeutics
Merck
Novartis
Pfizer
Seagen
Flag link:
Astellas reports data from Phase IIIb trial to treat VMS due to menopause
Astellas reports data from Phase IIIb trial to treat VMS due to menopause
Clinical Trials Arena
Astellas
clinical trials
fezolinetant
hot flashes
menopause
Flag link:
Mimetas and Astellas expand partnership to include automation and application support
Mimetas and Astellas expand partnership to include automation and application support
Biopharma Reporter
Mimetas
organ-on-a-chip
Astellas
automation
Flag link:
Astellas delves deeper into protein degrading drugs with Cullgen deal
Astellas delves deeper into protein degrading drugs with Cullgen deal
BioPharma Dive
Astellas
Cullgen
protein degradation
Flag link:
Biotech M&A is picking back up - here are the latest deals
Biotech M&A is picking back up - here are the latest deals
BioPharma Dive
Novartis
Chinook Therapeutics
Paratek
Sobi
CTI BioPharma
Astellas
Iveric Bio
Assertio Holdings
Spectrum Pharmaceuticals
Merck
Prometheus Biosciences
Pfizer
Seagen
Sanofi
Provention Bio
Sun Pharma
Concert Pharmaceuticals
BioNTech
InstaDeep
AstraXeneca
CinCor Pharma
Ipsen
Albireo
Chiesi
Amryt
Moderna Therapeutics
OriCiro Genomics
Flag link:
With Iveric Bio buyout, Astellas CEO Okamura acted on the company's mantra to be 'aggressive'
With Iveric Bio buyout, Astellas CEO Okamura acted on the company's mantra to be 'aggressive'
Fierce Pharma
Astellas
M&A
Iveric Bio
Naoki Okamura
Pharma CEOs
Flag link:

Pages